Amoxicillin/Clavulanate: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
||
Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
Infection, Bacterial: | Infection, Bacterial: | ||
* | *500mg-875 mg PO q12h | ||
Pneumonia, community-acquired | Pneumonia, community-acquired | ||
* | *2000mg ER PO q12h x 7-10 days | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Line 16: | Line 16: | ||
Otitis Media: | Otitis Media: | ||
* | *90mg/kg/day PO divided q12h x 10 days | ||
==Special Populations== | ==Special Populations== |
Revision as of 02:34, 19 July 2016
General
- Type: Antibiotic
- Dosage Forms: PO
- Common Trade Names: Augmentin
Adult Dosing
Infection, Bacterial:
- 500mg-875 mg PO q12h
Pneumonia, community-acquired
- 2000mg ER PO q12h x 7-10 days
Pediatric Dosing
Infection, Bacterial:
- 25-45 mg/kg PO divided q12h
Otitis Media:
- 90mg/kg/day PO divided q12h x 10 days
Special Populations
- Pregnancy: B
- Lactation: probably safe
- Renal Dosing
- Adult: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Pediatric: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Hepatic Dosing
- Adult: none
- Pediatric: none
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- steven johnson syndrome
- c.diff associated diarrhea
- hemolytic anemia
- leukopenia
- thrombocytopenia
- hepatitis
- seizures
Common
- diarrhea
- nausea
- rash
- pruritus
- vomiting
- glossitis
- transaminitis
Pharmacology
- Half-life: 1.1 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:Bactericidal, inhibits cell wall mucopeptide synthesis, inhibits beta lactamases
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014